Sygnature Discovery boosts growth of its In Vivo Pharmacology business with appointment of new Vice President
Sygnature Discovery is thrilled to announce the appointment of Fraser McIntosh as Vice President, In Vivo Pharmacology. Fraser will lead the company’s in vivo drug discovery operations worldwide, bringing 30 years of experience and a proven track record of success to the role.
Fraser’s extensive experience as a senior leader in drug discovery spans the pharmaceutical, biotechnology, and contract research organization sectors. He has championed numerous programs into clinical development and fostered cross-functional collaboration across diverse therapeutic areas and drug modalities.
At Sygnature, Fraser will spearhead the in vivo pharmacology business, setting strategic direction and driving scientific and operational excellence across the company’s UK and Canada sites. He’ll identify new commercial opportunities, integrate cutting-edge methodologies, and uphold the highest ethical and regulatory standards for all in vivo projects.
Commenting on the role, Fraser said: “I am delighted to join Sygnature Discovery at such an exciting point in the company’s growth and to contribute to this next phase of development. Sygnature’s talented scientific teams have a stellar reputation for delivering drug candidates across multiple therapeutic areas. I’m eager to leverage my drug discovery experience to build a global, integrated in vivo pharmacology department that supports Sygnature’s vision of becoming the leading global drug discovery CRO.”
Dr Simon Hirst, CEO of Sygnature Discovery, added: “Fraser’s expertise in leading in vivo pharmacology operations globally is a tremendous asset as we expand our customer offerings. His vision for commercial growth and scientific excellence aligns perfectly with Sygnature’s culture of innovation and collaboration.”
About Sygnature Discovery
Sygnature Discovery is a world-leading integrated drug discovery contract research organization based in the UK and Canada with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield, and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of over 1,000 employees, which includes 900 scientists, partners with global biotech, pharma and NFP organizations. Since 2011, Sygnature Discovery has delivered 50 novel pre-clinical and 30 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more.